Logo

Samsung Bioepis Eticovo's (etanercept-ykro- biosmilar) Receives FDA's Approval for All Eligible Indication

Share this

Samsung Bioepis Eticovo's (etanercept-ykro- biosmilar) Receives FDA's Approval for All Eligible Indication

Shots:

  • The approval is based on a P-III study results assessing Eticovo vs the reference product (Enbrel) in 596 patients with rheumatoid arthritis across 70 sites in 10 countries
  • The study resulted in ACR20 (80.8% vs 81.5%) for 52 wks. confirming results of 24 wks. study in (78.1% vs 80.3%)
  • Eticovo (etanercept-ykro) is a biosimilar to Enbrel- a TNF blocker targeted for the treatment of rheumatoid arthritis- ankylosing spondylitis- plaque psoriasis- psoriatic arthritis and polyarticular juvenile idiopathic arthritis

Click here to read full press release/ article

 Ref: Samsung Bioepis | Image: Samsung Bioepis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions